Login / Signup

Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE).

Naomi WijesinghaAachal KotechaPhilippe MargaronSobha Sivaprasad
Published in: Eye (London, England) (2024)
Keyphrases
  • age related macular degeneration
  • randomized controlled trial
  • endothelial cells